tiprankstipranks
Trending News
More News >
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
US Market

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Compare
1,638 Followers
See the Price Targets and Ratings of:

ARCT Analyst Ratings

Strong Buy
11Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Arcturus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARCT Stock 12 Month Forecast

Average Price Target

$61.44
▲(379.63%Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $61.44 with a high forecast of $140.00 and a low forecast of $32.00. The average price target represents a 379.63% change from the last price of $12.81.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","141":"$141","41.25":"$41.3","74.5":"$74.5","107.75":"$107.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$61.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,41.25,74.5,107.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,22.307692307692307,32.11538461538461,41.92307692307693,51.73076923076923,61.53846153846154,71.34615384615385,81.15384615384616,90.96153846153847,100.76923076923077,110.57692307692308,120.38461538461539,130.1923076923077,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,16.264615384615386,20.029230769230768,23.793846153846154,27.558461538461536,31.323076923076922,35.08769230769231,38.85230769230769,42.61692307692307,46.38153846153846,50.146153846153844,53.910769230769226,57.675384615384615,{"y":61.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,14,15.5,17,18.5,20,21.5,23,24.5,26,27.5,29,30.5,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.91,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.81,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.66,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.58,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.25,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$140.00Average Price Target$61.44Lowest Price Target$32.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ARCT
TipRanks AITipRanks
Not Ranked
TipRanks
$13
Hold
1.48%
Upside
Reiterated
05/30/25
Arcturus Therapeutics' stock score reflects a mix of strengths and challenges. Significant factors include financial performance with consistent net losses and declining revenues, mixed technical indicators, and a strategic focus highlighted in the earnings call. The EU approval of KOSTAIVE and extended cash runway are positives, but the lack of immediate financial milestones and valuation concerns weigh on the score.
Scotiabank Analyst forecast on ARCT
Greg HarrisonScotiabank
Scotiabank
$32
Buy
149.80%
Upside
Initiated
05/28/25
Arcturus Therapeutics initiated with an Outperform at ScotiabankArcturus Therapeutics initiated with an Outperform at Scotiabank
William Blair Analyst forecast on ARCT
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/21/25
William Blair Remains a Buy on Arcturus Therapeutics (ARCT)
Wells Fargo Analyst forecast on ARCT
Yanan ZhuWells Fargo
Wells Fargo
$50$45
Buy
251.29%
Upside
Reiterated
05/14/25
Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
Canaccord Genuity Analyst forecast on ARCT
Whitney IjemCanaccord Genuity
Canaccord Genuity
$68$66
Buy
415.22%
Upside
Reiterated
05/13/25
Arcturus Therapeutics price target lowered to $66 from $68 at CanaccordArcturus Therapeutics price target lowered to $66 from $68 at Canaccord
Cantor Fitzgerald Analyst forecast on ARCT
Pete StavropoulosCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/13/25
Cantor Fitzgerald reiterates Overweight Rating on Arcturus Therapeutics (ARCT)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ: ARCT).
Citi
$44
Buy
243.48%
Upside
Reiterated
05/12/25
Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
Leerink Partners Analyst forecast on ARCT
Lili (Aurélie) NsongoLeerink Partners
Leerink Partners
$63
Buy
391.80%
Upside
Reiterated
05/12/25
Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
H.C. Wainwright Analyst forecast on ARCT
Ed ArceH.C. Wainwright
H.C. Wainwright
$60
Buy
368.38%
Upside
Reiterated
04/11/25
Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
Guggenheim
$71$45
Buy
251.29%
Upside
Reiterated
04/10/25
Arcturus Therapeutics price target lowered to $45 from $71 at GuggenheimArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
BTIG
$57$58
Buy
352.77%
Upside
Reiterated
03/27/25
Arcturus Therapeutics (ARCT) PT Raised to $58 at BTIGBTIG analyst Thomas Shrader raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $58.00 (from $57.00) while maintaining a Buy rating.
Piper Sandler Analyst forecast on ARCT
Yasmeen RahimiPiper Sandler
Piper Sandler
$140
Buy
992.90%
Upside
Reiterated
03/07/25
Piper Sandler Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)
Laidlaw Analyst forecast on ARCT
Yale JenLaidlaw
Laidlaw
$79
Buy
516.71%
Upside
Reiterated
07/02/24
Laidlaw reiterates Buy Rating on Arcturus Therapeutics (ARCT)Laidlaw analyst Yale Jen reiterated a Buy rating and $79.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
WBB Securities Analyst forecast on ARCT
Stephen BrozakWBB Securities
WBB Securities
$25
Buy
95.16%
Upside
Upgraded
06/30/24
We arrive at our valuation using a sum-of-the-parts model: We assign a per-share value of $10.00 to the Lunar-OTC program and $9.00 to the LUNAR-CF program. And the balance of $6.00 to the different vaccine programs. Thus, we arrive at a 12- month per share price target of $25.00.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ARCT
TipRanks AITipRanks
Not Ranked
TipRanks
$13
Hold
1.48%
Upside
Reiterated
05/30/25
Arcturus Therapeutics' stock score reflects a mix of strengths and challenges. Significant factors include financial performance with consistent net losses and declining revenues, mixed technical indicators, and a strategic focus highlighted in the earnings call. The EU approval of KOSTAIVE and extended cash runway are positives, but the lack of immediate financial milestones and valuation concerns weigh on the score.
Scotiabank Analyst forecast on ARCT
Greg HarrisonScotiabank
Scotiabank
$32
Buy
149.80%
Upside
Initiated
05/28/25
Arcturus Therapeutics initiated with an Outperform at ScotiabankArcturus Therapeutics initiated with an Outperform at Scotiabank
William Blair Analyst forecast on ARCT
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/21/25
William Blair Remains a Buy on Arcturus Therapeutics (ARCT)
Wells Fargo Analyst forecast on ARCT
Yanan ZhuWells Fargo
Wells Fargo
$50$45
Buy
251.29%
Upside
Reiterated
05/14/25
Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
Canaccord Genuity Analyst forecast on ARCT
Whitney IjemCanaccord Genuity
Canaccord Genuity
$68$66
Buy
415.22%
Upside
Reiterated
05/13/25
Arcturus Therapeutics price target lowered to $66 from $68 at CanaccordArcturus Therapeutics price target lowered to $66 from $68 at Canaccord
Cantor Fitzgerald Analyst forecast on ARCT
Pete StavropoulosCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/13/25
Cantor Fitzgerald reiterates Overweight Rating on Arcturus Therapeutics (ARCT)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ: ARCT).
Citi
$44
Buy
243.48%
Upside
Reiterated
05/12/25
Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
Leerink Partners Analyst forecast on ARCT
Lili (Aurélie) NsongoLeerink Partners
Leerink Partners
$63
Buy
391.80%
Upside
Reiterated
05/12/25
Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
H.C. Wainwright Analyst forecast on ARCT
Ed ArceH.C. Wainwright
H.C. Wainwright
$60
Buy
368.38%
Upside
Reiterated
04/11/25
Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
Guggenheim
$71$45
Buy
251.29%
Upside
Reiterated
04/10/25
Arcturus Therapeutics price target lowered to $45 from $71 at GuggenheimArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
BTIG
$57$58
Buy
352.77%
Upside
Reiterated
03/27/25
Arcturus Therapeutics (ARCT) PT Raised to $58 at BTIGBTIG analyst Thomas Shrader raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $58.00 (from $57.00) while maintaining a Buy rating.
Piper Sandler Analyst forecast on ARCT
Yasmeen RahimiPiper Sandler
Piper Sandler
$140
Buy
992.90%
Upside
Reiterated
03/07/25
Piper Sandler Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)
Laidlaw Analyst forecast on ARCT
Yale JenLaidlaw
Laidlaw
$79
Buy
516.71%
Upside
Reiterated
07/02/24
Laidlaw reiterates Buy Rating on Arcturus Therapeutics (ARCT)Laidlaw analyst Yale Jen reiterated a Buy rating and $79.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
WBB Securities Analyst forecast on ARCT
Stephen BrozakWBB Securities
WBB Securities
$25
Buy
95.16%
Upside
Upgraded
06/30/24
We arrive at our valuation using a sum-of-the-parts model: We assign a per-share value of $10.00 to the Lunar-OTC program and $9.00 to the LUNAR-CF program. And the balance of $6.00 to the different vaccine programs. Thus, we arrive at a 12- month per share price target of $25.00.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcturus Therapeutics

1 Month
xxx
Success Rate
7/10 ratings generated profit
70%
Average Return
-4.19%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of -4.19% per trade.
3 Months
xxx
Success Rate
4/9 ratings generated profit
44%
Average Return
-5.46%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -5.46% per trade.
1 Year
Success Rate
2/9 ratings generated profit
22%
Average Return
-29.42%
reiterated a buy rating 23 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -29.42% per trade.
2 Years
xxx
Success Rate
4/18 ratings generated profit
22%
Average Return
-27.54%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -27.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARCT Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
12
14
19
15
16
Buy
4
3
4
5
7
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
17
23
20
23
In the current month, ARCT has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ARCT average Analyst price target in the past 3 months is 61.44.
Each month's total comprises the sum of three months' worth of ratings.

ARCT Financial Forecast

ARCT Earnings Forecast

Next quarter’s earnings estimate for ARCT is -$0.94 with a range of -$1.76 to -$0.49. The previous quarter’s EPS was -$0.52. ARCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.
Next quarter’s earnings estimate for ARCT is -$0.94 with a range of -$1.76 to -$0.49. The previous quarter’s EPS was -$0.52. ARCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.

ARCT Sales Forecast

Next quarter’s sales forecast for ARCT is $18.68M with a range of $0.00 to $29.70M. The previous quarter’s sales results were $25.48M. ARCT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.
Next quarter’s sales forecast for ARCT is $18.68M with a range of $0.00 to $29.70M. The previous quarter’s sales results were $25.48M. ARCT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.

ARCT Stock Forecast FAQ

What is ARCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is 61.44.
    What is ARCT’s upside potential, based on the analysts’ average price target?
    Arcturus Therapeutics has 379.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARCT a Buy, Sell or Hold?
          Arcturus Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Arcturus Therapeutics’s price target?
            The average price target for Arcturus Therapeutics is 61.44. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $140.00 ,the lowest forecast is $32.00. The average price target represents 379.63% Increase from the current price of $12.81.
              What do analysts say about Arcturus Therapeutics?
              Arcturus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of ARCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis